Recent discussions on X about Penumbra Inc (PEN) have centered around insider stock sales and analyst ratings, sparking a flurry of opinions among investors. Many users are dissecting the implications of significant transactions by company executives, with some expressing concern over the timing and volume of these sales as reported in recent financial news. The sentiment is mixed, as others point out the company's strong market position in the medical devices sector, suggesting confidence in long-term growth.
Additionally, posts on X highlight a bullish outlook from certain analysts, with some noting a 'Moderate Buy' consensus and specific price targets that suggest optimism about Penumbra's future performance. There's a palpable curiosity about whether recent institutional buying signals a positive shift, keeping the conversation lively and speculative. These discussions reflect a broader interest in how insider moves and analyst perspectives might shape the stock's trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Penumbra Inc Congressional Stock Trading
Members of Congress have traded $PEN stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 07/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Penumbra Inc Insider Trading Activity
Penumbra Inc insiders have traded $PEN stock on the open market 169 times in the past 6 months. Of those trades, 0 have been purchases and 169 have been sales.
Here’s a breakdown of recent trading of $PEN stock by insiders over the last 6 months:
- ADAM ELSESSER (CEO) has made 0 purchases and 88 sales selling 210,940 shares for an estimated $55,623,664.
- ARANI BOSE has made 0 purchases and 22 sales selling 36,000 shares for an estimated $9,997,803.
- JOHANNA ROBERTS (EVP, Gen. Counsel & Secretary) has made 0 purchases and 49 sales selling 4,500 shares for an estimated $1,222,404.
- MAGGIE YUEN (Chief Financial Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $1,098,020.
- THOMAS WILDER has made 0 purchases and 3 sales selling 1,092 shares for an estimated $280,683.
- HARPREET GREWAL has made 0 purchases and 2 sales selling 386 shares for an estimated $104,061.
- BRIDGET O'ROURKE has made 0 purchases and 3 sales selling 200 shares for an estimated $55,164.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Penumbra Inc Hedge Fund Activity
We have seen 255 institutional investors add shares of Penumbra Inc stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 883,098 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $236,149,236
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 625,663 shares (-98.7%) from their portfolio in Q2 2025, for an estimated $160,563,895
- INVESCO LTD. added 582,369 shares (+1139.3%) to their portfolio in Q2 2025, for an estimated $149,453,356
- CITADEL ADVISORS LLC removed 565,317 shares (-72.1%) from their portfolio in Q2 2025, for an estimated $145,077,301
- HOLOCENE ADVISORS, LP removed 402,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $103,251,487
- BAILLIE GIFFORD & CO added 233,132 shares (+33.8%) to their portfolio in Q2 2025, for an estimated $59,828,665
- NORGES BANK added 215,218 shares (+94.0%) to their portfolio in Q2 2025, for an estimated $55,231,395
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Penumbra Inc Government Contracts
We have seen $300,263 of award payments to $PEN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- POST SURGERY - PACKING COILS: $26,900
- EXPRESS REPORT: IMPLANT: $22,570
- VISN 12 PROSTHETICS PURCHASES FY24 WITH PENUMBRA INC.: $21,684
- PROSTHETICS:SURGICAL IMPLANTS COILS: $21,320
- PROSTHETICS:IMPLANT: $20,880
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Penumbra Inc Analyst Ratings
Wall Street analysts have issued reports on $PEN in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 09/02/2025
- Canaccord Genuity issued a "Buy" rating on 07/30/2025
- Truist Securities issued a "Buy" rating on 07/30/2025
- Baird issued a "Outperform" rating on 07/30/2025
- RBC Capital issued a "Outperform" rating on 07/30/2025
- UBS issued a "Buy" rating on 07/30/2025
- Wells Fargo issued a "Overweight" rating on 07/30/2025
To track analyst ratings and price targets for Penumbra Inc, check out Quiver Quantitative's $PEN forecast page.
Penumbra Inc Price Targets
Multiple analysts have issued price targets for $PEN recently. We have seen 11 analysts offer price targets for $PEN in the last 6 months, with a median target of $310.0.
Here are some recent targets:
- Vijay Kumar from Evercore ISI Group set a target price of $300.0 on 09/02/2025
- Kallum Titchmarsh from Morgan Stanley set a target price of $266.0 on 07/31/2025
- Jason Mills from Canaccord Genuity set a target price of $350.0 on 07/30/2025
- David Rescott from Truist Securities set a target price of $310.0 on 07/30/2025
- David Rescott from Baird set a target price of $285.0 on 07/30/2025
- Shagun Singh from RBC Capital set a target price of $325.0 on 07/30/2025
- Larry Biegelsen from Wells Fargo set a target price of $290.0 on 07/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
